Dr Shah on 5-Year Outcomes With Pembrolizumab/Chemo in Esophageal Cancer
Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.
Manisha Shah Solid Tumor Service Gastrointestinal Oncology Program Weill Cornell Medicine Advanced Digestive Disease Newyork Presbyterian
Source: onclive.com